Integra LifeSciences Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Integra LifeSciences (IART) Reports In-Line Q2 EPS, Revenues Miss; Boosts FY18 EPS/Revenue Mid-Point Outlooks Below Consensus
July 25, 2018 6:11 AM EDTIntegra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.60, in-line with the analyst estimate of $0.60. Revenue for the quarter came in at $366.2 million versus the consensus estimate of $368.25 million.
Revenue Increased 29.8% to $366.2 million; Organic Revenue Increased 3.4% Reported EPS of $0.14; Adjusted EPS of $0.60Raises Low-End of Full-Year Total Revenue and EPS GuidanceSuccessfully Exits First Wave of Codman Transition Services AgreementsSecond Quarter 2018 Consolidated Results
Reported revenue was $366.2 million, an increase of 29.8% compared to the second quarter of 2017;... More